title: Initial analysis of Pro-Qura: a multi-institutional database of prostate brachytherapy dosimetry.
abstract: OBJECTIVE
  The study aimed to analyze the Pro-Qura database in terms of patient implant sequence number for each institution to determine evidence for a dosimetric learning curve.
  
  
  METHODS
  In the Pro-Qura database, 2833 of a total of 4614 postplans from 57 brachytherapists were analyzed for evidence of a dosimetric learning curve. The median time between implant and postimplant CT scan was 30 days. I-125 was used in 2123 patients (1687 monotherapy and 536 boost) and Pd-103 in 710 patients (367 monotherapy and 343 boost). Preimplant prostate volume was 35.3 and 32.9 cm3 in the I-125 and Pd-103 cohorts, respectively. The mean I-125 seed activity was 0.32 and 0.26 mCi for monotherapy and boost, whereas for Pd-103 the mean seed activity was 1.59 and 1.27 mCi, respectively. Postimplant dosimetry was performed in a standardized fashion by overlaying the preimplant ultrasound and the postimplant CT scan. Criteria for implant adequacy included a D90 >90% and a V100 >80% for both isotopes. An adequate V150 was defined as <60% for I-125 and <75% for Pd-103.
  
  
  RESULTS
  The mean V100 and D90 were 88.9% and 101.9% of prescription dose, respectively. When analyzed in terms of patient sequence number for each institution, the mean V100 for the first 10 patients was 87.4% and increased to 88.6% for patients 11-20 (p = 0.036). Similarly, the mean D90 for the first 10 patients was 98.9%, whereas for the second cohort of 10 patients the mean D90 increased to 102.2% (p = 0.001). In terms of mean V100 and D90, there was minimal further change for subsequent 10 patient institutional groupings of patient sequence numbers. For the first 10 cases, 27.2% were deemed "too cool" (V100 <80% and/or D90 <90%). Approximately 16% of all implants were deemed "too hot" (D90 >140% or V150 >60% for I-125 or >75% for Pd-103).
  
  
  CONCLUSIONS
  Although a learning curve exists for prostate brachytherapy, high-quality brachytherapy is achievable in approximately 75-80% of patients treated at community centers.
authors.affiliation: Schiffler Cancer Center, Wheeling Hospital, Wheeling, WV 26003-6300, USA. gmerrick@urologicresearchinstitute.org
authors.forename: Gregory S
authors.initials: GS
authors.lastname: Merrick
authors.forename: Peter D
authors.initials: PD
authors.lastname: Grimm
authors.forename: John
authors.initials: J
authors.lastname: Sylvester
authors.forename: John C
authors.initials: JC
authors.lastname: Blasko
authors.forename: Wayne M
authors.initials: WM
authors.lastname: Butler
authors.forename: Zachariah A
authors.initials: ZA
authors.lastname: Allen
authors.forename: Usman-Ul-Haq
authors.initials: UU
authors.lastname: Chaudhry
authors.forename: Anthony
authors.initials: A
authors.lastname: Mazza
authors.forename: Mike
authors.initials: M
authors.lastname: Sitter
mesh_terms: D001918:Brachytherapy; D016208:Databases, Factual; D004307:Dose-Response Relationship, Radiation; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use; D008297:Male; D010165:Palladium / Q000627:therapeutic use; D011471:Prostatic Neoplasms / Q000532:radiotherapy*; D011868:Radioisotopes / Q000627:therapeutic use; D011879:Radiotherapy Dosage
chemical_list: D007457:Iodine Radioisotopes; D011868:Radioisotopes; D010165:Palladium